Neuromyelitis Optica Spectrum Disorder Clinical Trials in Wuhan
4 recruitingWuhan, China
Showing 1–4 of 4 trials
Recruiting
Phase 1
Safety and Pharmacodynamics of QH103 Cell Injection in the Treatment of Patients With Relapsed/Refractory Antibody-Mediated Neurological Autoimmune Diseases.
Neuromyelitis Optica Spectrum Disorder (NMOSD)Multiple Sclerosis (MS)Myasthenia Gravis (MG)+3 more
Tongji Hospital6 enrolled1 locationNCT07526493
Recruiting
Registry of Patients With AQP4+ NMOSD Treated With Alexion C5 Inhibitor Therapies
Neuromyelitis Optica Spectrum DisorderNMOSDAQP4+ NMOSD
Alexion Pharmaceuticals, Inc.122 enrolled33 locationsNCT05966467
Recruiting
Phase 2Phase 3
A Clinical Study of B001 Injection in the Treatment of Neuromyelitis Optica Spectrum Disorders(NMOSD)
Neuromyelitis Optica Spectrum Disorders
Shanghai Jiaolian Drug Research and Development Co., Ltd132 enrolled51 locationsNCT06413654
Recruiting
Biomarkers in Autoimmune Disease of Nervous System
Myasthenia GravisAutoimmune EncephalitisMultiple Sclerosis+8 more
Tongji Hospital50,000 enrolled1 locationNCT06502015